Privia Health Group (PRVA)
NASDAQ:PRVA
US Market
Holding PRVA?
Track your performance easily

Privia Health Group (PRVA) Stock Forecast & Price Target

173 Followers
See the Price Targets and Ratings of:

PRVA Analyst Ratings

Strong Buy
13Ratings
12 Buy
1 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Privia
Health Group
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PRVA Stock 12 Month Forecast

Average Price Target

$24.64
▲(39.60% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Privia Health Group in the last 3 months. The average price target is $24.64 with a high forecast of $28.00 and a low forecast of $19.00. The average price target represents a 39.60% change from the last price of $17.65.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","29":"$29","19.25":"$19.25","22.5":"$22.5","25.75":"$25.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,19.25,22.5,25.75,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"Apr<br/>2024","9":"Jul<br/>2024","12":"Oct<br/>2024","25":"Oct<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.59,18.39076923076923,19.19153846153846,19.99230769230769,20.793076923076924,21.593846153846155,22.394615384615385,23.195384615384615,23.996153846153845,24.79692307692308,25.597692307692306,26.39846153846154,27.19923076923077,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.59,18.13230769230769,18.674615384615386,19.216923076923077,19.75923076923077,20.301538461538463,20.843846153846155,21.386153846153846,21.92846153846154,22.470769230769232,23.013076923076923,23.555384615384618,24.09769230769231,{"y":24.64,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.59,17.698461538461537,17.806923076923077,17.915384615384614,18.023846153846154,18.13230769230769,18.24076923076923,18.34923076923077,18.45769230769231,18.566153846153846,18.674615384615386,18.783076923076923,18.89153846153846,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.83,"date":1698364800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.52,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.29,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.69,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.32,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.57,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.74,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.15,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.08,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.99,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.66,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.59,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$28.00Average Price Target$24.64Lowest Price Target$19.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity
$26
Buy
47.31%
Upside
Reiterated
08/08/24
Buy Rating Affirmed for Privia Health Group Amid Solid Financials and Positive 2024 Outlook
Leerink Partners
$26
Buy
47.31%
Upside
Reiterated
08/08/24
Analysts Are Bullish on Top Healthcare Stocks: Celldex (CLDX), Privia Health Group (PRVA)
JMP Securities
$25
Buy
41.64%
Upside
Reiterated
08/08/24
Privia Health Group's Strong Q2 Performance and Upward Outlook Prompt Buy Rating
Jefferies
$25
Buy
41.64%
Upside
Reiterated
05/15/24
We believe concerns around margins & FCF are addressable while in-line results against a challenging back- drop for VBC businesses deserve credit. From current levels at <20x FY25 EBITDA we think the story is simple: an achievable +20% medium term EBITDA growth outlook & best-in-class FCF characteristics warrant a higher multiple. Reit Buy, PT to $25 (26x FY25 EBITDA based on coverage EV/EBITDA-to- Growth). 1Q24 the Board. PRVA delivered a solid 1Q24 with top-line & volume KPIs (Implemented Providers & Attributed Lives) tracking modestly ahead of Street -- perhaps implying some upside vs. the FY24 top-line guide -- while Care Margin & EBITDA were largely in line.
Bank of America Securities
$21
Hold
18.98%
Upside
Reiterated
05/09/24
Privia Health Group: Hold Rating Maintained Amid Steady Performance and Cautious Outlook

Best Analysts Covering Privia Health Group

Which Analyst Should I Follow If I Want to Buy PRVA and Sell After:
1 Month
xxx
Success Rate
7/18 ratings generated profit
39%
Average Return
+0.13%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 38.89% of your transactions generating a profit, with an average return of +0.13% per trade.
3 Months
xxx
Success Rate
8/18 ratings generated profit
44%
Average Return
+0.23%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +0.23% per trade.
1 Year
Whit MayoLeerink Partners
Success Rate
6/18 ratings generated profit
33%
Average Return
-4.24%
reiterated a buy rating 3 months ago
Copying Whit Mayo's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -4.24% per trade.
2 Years
xxx
Success Rate
1/18 ratings generated profit
6%
Average Return
-20.21%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 5.56% of your transactions generating a profit, with an average return of -20.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRVA Analyst Recommendation Trends

Rating
May 24
Jul 24
Aug 24
Sep 24
Oct 24
Strong Buy
2
1
1
0
0
Buy
12
10
20
13
14
Hold
4
3
3
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
14
24
14
15
In the current month, PRVA has received 14 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. PRVA average Analyst price target in the past 3 months is $24.64.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

PRVA Financial Forecast

PRVA Earnings Forecast

Next quarter’s earnings estimate for PRVA is $0.05 with a range of $0.03 to $0.07. The previous quarter’s EPS was $0.03. PRVA beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.75% of the time in the same period. In the last calendar year PRVA has Underperformed its overall industry.
Next quarter’s earnings estimate for PRVA is $0.05 with a range of $0.03 to $0.07. The previous quarter’s EPS was $0.03. PRVA beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.75% of the time in the same period. In the last calendar year PRVA has Underperformed its overall industry.

PRVA Sales Forecast

Next quarter’s sales forecast for PRVA is $414.17M with a range of $394.79M to $426.68M. The previous quarter’s sales results were $422.33M. PRVA beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.19% of the time in the same period. In the last calendar year PRVA has Outperformed its overall industry.
Next quarter’s sales forecast for PRVA is $414.17M with a range of $394.79M to $426.68M. The previous quarter’s sales results were $422.33M. PRVA beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.19% of the time in the same period. In the last calendar year PRVA has Outperformed its overall industry.

PRVA Stock Forecast FAQ

What is PRVA’s average 12-month price target, according to analysts?
Based on analyst ratings, Privia Health Group’s 12-month average price target is $24.64.
    What is PRVA’s upside potential, based on the analysts’ average price target?
    Privia Health Group has 39.60% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PRVA a Buy, Sell or Hold?
          Privia Health Group has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Privia Health Group’s price target?
            The average price target for Privia Health Group is $24.64. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $28.00 ,the lowest forecast is $19.00. The average price target represents 39.60% Increase from the current price of $17.65.
              What do analysts say about Privia Health Group?
              Privia Health Group’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of PRVA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis